Consistently, while sorafenib mono‐treatment resulted in prominent increase of apoptotic cells, the concurrent knockdown of SESN2 forwardly aggravated the death of HCC cells (Figure 3F,G). The gene discussed is SESN2; the disease is hepatocellular carcinoma.